Skip to main content
Funded Studies

Christopher G. Goetz, MD

Professor of Neurological Sciences and Pharmacology at Rush University Medical Center

Location: Chicago, IL United States

Christopher G. Goetz, MD, is professor in the Department of Neurological Sciences and Pharmacology and serves as director of the Movement Disorders Program at Rush University Medical Center in Chicago. Dr. Goetz is also the United Parkinson Foundation Professor of Neurology. He is the director of the Rush Parkinson’s Disease Foundation Parkinson’s Disease Research Center.

Dr. Goetz is a senior Fulbright Scholar and worked for two years at the College de France in Paris. He has published over 400 peer-reviewed articles and more than 200 book chapters in the field.  He has also published and co-authored 14 books and monographs. He has been one of two co-editors-in-chief of the Movement Disorders journal, and is the former editor-in-chief of Clinical Neuropharmacology. He is currently an officer of the International Parkinson and Movement Disorder Society (MDS).

Dr. Goetz’s major interests are the pharmacology of various movement disorders and the development of rating scales for measurement of disease impact in movement disorders.  He led the MDS Task Force to develop a new version of the Unified Parkinson’s Disease Rating Scale (UPDRS), termed the MDS-UPDRS, unveiled in 2008.  He also developed the Unified Dyskinesia Rating Scale (UDysRS) with Dr. Stebbins and leads the current MDS program to develop validated official non-English translations of both the MDS-UPDRS and UDysRS.


Associated Grants

  • Unified Dyskinesia Rating Scale: Application for FDA Designation as a Preferred Scale for Assessing Dyskinesia in Parkinson’s Disease

    2015


  • Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease

    2012


  • Validation of Dyskinesia Rating Scales

    2009


  • The Unified Dyskinesia Rating Scale (UDysRS): Clinimetric Testing Program

    2006


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.